Entrada Therapeutics Past Earnings Performance
Past criteria checks 0/6
Entrada Therapeutics's earnings have been declining at an average annual rate of -20.7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 146.5% per year.
Key information
-20.7%
Earnings growth rate
59.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 146.5% |
| Return on equity | -2.8% |
| Net Margin | -5.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Revenue & Expenses BreakdownBeta
How Entrada Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 129 | -7 | 32 | 0 |
| 30 Sep 23 | 87 | -22 | 34 | 67 |
| 30 Jun 23 | 43 | -82 | 33 | 67 |
| 31 Mar 23 | 25 | -80 | 32 | 67 |
| 31 Dec 22 | 0 | -95 | 31 | 0 |
| 30 Sep 22 | 0 | -88 | 27 | 12 |
| 30 Jun 22 | 0 | -78 | 24 | 23 |
| 31 Mar 22 | 0 | -64 | 19 | 30 |
| 31 Dec 21 | 0 | -51 | 15 | 36 |
| 30 Sep 21 | 0 | -41 | 11 | 30 |
| 30 Jun 21 | 0 | -34 | 9 | 25 |
| 31 Mar 21 | 0 | -29 | 7 | 23 |
| 31 Dec 20 | 0 | -27 | 6 | 21 |
Quality Earnings: TRDA is currently unprofitable.
Growing Profit Margin: TRDA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRDA is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.
Accelerating Growth: Unable to compare TRDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TRDA has a negative Return on Equity (-2.76%), as it is currently unprofitable.